Multiagent chemotherapy studied in a xenograft model of medulloblastoma/primitive neuroectodermal tumour: Analysis of the VETOPEC regimen-Reference-Cited by-同舟云学术

Multiagent chemotherapy studied in a xenograft model of medulloblastoma/primitive neuroectodermal tumour: Analysis of the VETOPEC regimen

Published:2008-01 Issue:1 Volume:15 Page:49-54
ISSN:0967-5868
Container-title:Journal of Clinical Neuroscience
language:en
Short-container-title:Journal of Clinical Neuroscience

Author:

White Les,Sterling-Levis Katy

Publisher

Elsevier BV

Subject

Physiology (medical),Neurology (clinical),Neurology,General Medicine,Surgery

Reference23 articles.

1. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group;White;J Clin Oncol,1994

2. A dose intensive, cyclophosphamide-based regimen (VETOPEC) for relapsed progressive or advanced solid tumors of childhood: a report from the Australian and New Zealand Children’s Cancer Study Group;Carpenter;Cancer,1997

3. Ganulocyte–macrophage colony-stimulating factor in association with high dose chemotherapy (VETOPEC) for childhood solid tumors: A report from the Australian and New Zealand Children’s Cancer Study Group;McCowage;Med Ped Oncol,1997

4. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: Promising initial response to a VETOPEC-based regimen: A study of the Australian and New Zealand Children’s Cancer Study Group (ANZCCSG);White;J Ped Hemat Oncol,1998

5. Lal A, White L, Mongrovius R. Intensive cyclophosphamide-based sequential regimen followed by autologous peripheral blood stem cells (PBSC) and filgrastim in poor-risk childhood solid tumors (VETOPEC II): a phase I/II trial of the Australian and New Zealand Children’s Cancer Study Group. 1999 ASCO Annual Meeting. Abstract 2205. 1999.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma;Cancer Cell;2014-04